CONTACT US

SIGN UP FOR OUR NEWSLETTER

  • LinkedIn - White Circle

SINGAPORE

LaunchPad @ one-north

71 Ayer Rajah Crescent

#03-20/21/23/24

Singapore 139951

CHINA

Biotech Innovation Works

No.29 Life Park Road

Room 202-010, Block D

Changping District, Beijing, China, 102206

UNITED STATES

1 Broadway, Cambridge MA 02142 USA

© 2019 by Esco Ventures Pte. Ltd.

Carmine Therapeutics

We're proud to announce that Carmine Therapeutics was incorporated in Jan 2019 and it's a Boston-Singapore Esco Ventures X company, working on pioneering a powerful new class of medicines based on red blood cell extracellular vesicles (RBCEVs). In addition to the exciting technology, Carmine also has a strong scientific advisory board consisting of industry and scientific experts. 

Prof. Harvey Lodish

Scientific Advisor

  • Professor, MIT; Founding Member, Whitehead Institute

  • Member of U.S. National Academy of Sciences

  • Founder and SAB of Genzyme (sold to Sanofi for USD20.2B), Millennium Pharma (sold to Takeda for USD9B), Rubius Therapeutics (preclinical IPO at USD1.8B)

Prof. Minh Le

Scientific Advisor

  • Professor, MIT; Founding Member, Whitehead Institute

  • Member of U.S. National Academy of Sciences

  • Founder and SAB of Genzyme (sold to Sanofi for USD20.2B), Millennium Pharma (sold to Takeda for USD9B), Rubius Therapeutics (preclinical IPO at USD1.8B)

Prof. Shi Jiahai

Scientific Advisor

  • Professor, MIT; Founding Member, Whitehead Institute

  • Member of U.S. National Academy of Sciences

  • Founder and SAB of Genzyme (sold to Sanofi for USD20.2B), Millennium Pharma (sold to Takeda for USD9B), Rubius Therapeutics (preclinical IPO at USD1.8B)

Prof. Jianzhu Chen

Scientific Advisor

  • Professor, MIT; Founding Member, Whitehead Institute

  • Member of U.S. National Academy of Sciences

  • Founder and SAB of Genzyme (sold to Sanofi for USD20.2B), Millennium Pharma (sold to Takeda for USD9B), Rubius Therapeutics (preclinical IPO at USD1.8B)